SIA
ALXN

Sit Investment Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Sit Investment Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,350
Closed -$3.25M – 558
2018
Q3 		$3.25M Sell
23,350
-4,425
-16% -$555K 0.08% 211
2018
Q2 		$3.45M Sell
27,775
-1,975
-7% -$231K 0.09% 223
2018
Q1 		$3.32M Sell
29,750
-220
-0.7% -$26.3K 0.08% 232
2017
Q4 		$3.58M Hold
29,970
– – 0.09% 224
2017
Q3 		$4.2M Sell
29,970
-650
-2% -$88.3K 0.1% 202
2017
Q2 		$3.73M Sell
30,620
-6,600
-18% -$768K 0.09% 208
2017
Q1 		$4.51M Sell
37,220
-2,275
-6% -$293K 0.11% 189
2016
Q4 		$4.83M Sell
39,495
-1,350
-3% -$165K 0.13% 179
2016
Q3 		$5M Sell
40,845
-2,710
-6% -$349K 0.13% 181
2016
Q2 		$5.08M Sell
43,555
-1,200
-3% -$170K 0.13% 169
2016
Q1 		$6.23M Sell
44,755
-2,615
-6% -$384K 0.11% 148
2015
Q4 		$9.04M Sell
47,370
-650
-1% -$114K 0.17% 125
2015
Q3 		$7.51M Sell
48,020
-1,800
-4% -$328K 0.14% 133
2015
Q2 		$9.01M Sell
49,820
-2,910
-6% -$502K 0.16% 122
2015
Q1 		$9.14M Sell
52,730
-23,750
-31% -$4.3M 0.16% 125
2014
Q4 		$14.2M Sell
76,480
-3,775
-5% -$699K 0.23% 116
2014
Q3 		$13.3M Sell
80,255
-19,472
-20% -$3.2M 0.23% 117
2014
Q2 		$15.6M Sell
99,727
-415
-0.4% -$65.5K 0.27% 119
2014
Q1 		$15.2M Sell
100,142
-18,385
-16% -$2.92M 0.27% 117
2013
Q4 		$15.8M Sell
118,527
-1,000
-0.8% -$120K 0.28% 110
2013
Q3 		$13.9M Sell
119,527
-23,858
-17% -$2.62M 0.27% 115
2013
Q2 		$13.2M Buy
+143,385
New +$13.8M 0.27% 107

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sit Investment Associates's ALXN Position: Q4 2018 in Review

Sit Investment Associates sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 23,350 shares — an estimated $3.25M sold.

Sit Investment Associates first reported a position in ALXN in Q2 2013 and held it in 22 quarters. The position peaked at $15.8M in Q4 2013. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Sit Investment Associates reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Sit Investment Associates sold 23,350 Alexion Pharmaceuticals shares in Q4 2018, an estimated $3.25M.
  • Sit Investment Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Sit Investment Associates's Alexion Pharmaceuticals position peaked at $15.8M in Q4 2013.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Sit Investment Associates's 13F filing for Q4 2018, filed 14 Jan 2019.